681 related articles for article (PubMed ID: 31835074)
1. Assessing the validity of EQ-5D-5L in people with head & neck cancer: Does a generic quality of life measure perform as well as a disease-specific measure in a patient population?
Davies A; Waylen A; Leary S; Thomas S; Pring M; Janssen B; Beynon R; Lang S; Schimansky S; Hurley K; Ness A
Oral Oncol; 2020 Feb; 101():104504. PubMed ID: 31835074
[TBL] [Abstract][Full Text] [Related]
2. Mapping the EORTC QLQ-C30 and QLQ-H&N35, onto EQ-5D-5L and HUI-3 indices in patients with head and neck cancer.
Noel CW; Stephens RF; Su JS; Xu W; Krahn M; Monteiro E; Goldstein DP; Giuliani M; Hansen AR; de Almeida JR
Head Neck; 2020 Sep; 42(9):2277-2286. PubMed ID: 32333829
[TBL] [Abstract][Full Text] [Related]
3. Mapping EORTC QLQ-C30 and FACT-G onto EQ-5D-5L index for patients with cancer.
Hagiwara Y; Shiroiwa T; Taira N; Kawahara T; Konomura K; Noto S; Fukuda T; Shimozuma K
Health Qual Life Outcomes; 2020 Nov; 18(1):354. PubMed ID: 33143687
[TBL] [Abstract][Full Text] [Related]
4. Reference values of EORTC QLQ-C30, EORTC QLQ-BR23, and EQ-5D-5L for women with non-metastatic breast cancer at diagnosis and 2 years after.
Miret C; Orive M; Sala M; García-Gutiérrez S; Sarasqueta C; Legarreta MJ; Redondo M; Rivero A; Castells X; Quintana JM; Garin O; Ferrer M;
Qual Life Res; 2023 Apr; 32(4):989-1003. PubMed ID: 36630024
[TBL] [Abstract][Full Text] [Related]
5. Measuring the Time to Deterioration for Health-Related Quality of Life in Patients With Metastatic Breast Cancer Using a Web-Based Monitoring Application: Longitudinal Cohort Study.
Brusniak K; Feisst M; Sebesteny L; Hartkopf A; Graf J; Engler T; Schneeweiss A; Wallwiener M; Deutsch TM
JMIR Cancer; 2021 Oct; 7(4):e25776. PubMed ID: 34636732
[TBL] [Abstract][Full Text] [Related]
6. "The validity of the EQ-5D-5L in measuring quality of life benefits of breast reconstruction".
Kouwenberg CAE; Kranenburg LW; Visser MS; Busschbach JJ; Mureau MAM
J Plast Reconstr Aesthet Surg; 2019 Jan; 72(1):52-61. PubMed ID: 30270015
[TBL] [Abstract][Full Text] [Related]
7. Which Questionnaire Should Be Used to Measure Quality-of-Life Utilities in Patients with Acute Leukemia? An Evaluation of the Validity and Interpretability of the EQ-5D-5L and Preference-Based Questionnaires Derived from the EORTC QLQ-C30.
van Dongen-Leunis A; Redekop WK; Uyl-de Groot CA
Value Health; 2016; 19(6):834-843. PubMed ID: 27712712
[TBL] [Abstract][Full Text] [Related]
8. How Should We Capture Health State Utility in Dementia? Comparisons of DEMQOL-Proxy-U and of Self- and Proxy-Completed EQ-5D-5L.
Martin A; Meads D; Griffiths AW; Surr CA
Value Health; 2019 Dec; 22(12):1417-1426. PubMed ID: 31806199
[TBL] [Abstract][Full Text] [Related]
9. Comparing the mapping between EQ-5D-5L, EQ-5D-3L and the EORTC-QLQ-C30 in non-small cell lung cancer patients.
Khan I; Morris S; Pashayan N; Matata B; Bashir Z; Maguirre J
Health Qual Life Outcomes; 2016 Apr; 14():60. PubMed ID: 27072351
[TBL] [Abstract][Full Text] [Related]
10. Responsiveness of the generic EQ-5D summary measure compared to the disease-specific EORTC QLQ C-30.
Krabbe PF; Peerenboom L; Langenhoff BS; Ruers TJ
Qual Life Res; 2004 Sep; 13(7):1247-53. PubMed ID: 15473503
[TBL] [Abstract][Full Text] [Related]
11. EuroQol (EQ-5D-5L) Validity in Assessing the Quality of Life in Adults With Asthma: Cross-Sectional Study.
Hernandez G; Garin O; Dima AL; Pont A; Martí Pastor M; Alonso J; Van Ganse E; Laforest L; de Bruin M; Mayoral K; Serra-Sutton V; Ferrer M;
J Med Internet Res; 2019 Jan; 21(1):e10178. PubMed ID: 30672744
[TBL] [Abstract][Full Text] [Related]
12. Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048.
Rischin D; Harrington KJ; Greil R; Soulières D; Tahara M; de Castro G; Psyrri A; Braña I; Neupane P; Bratland Å; Fuereder T; Hughes BGM; Mesía R; Ngamphaiboon N; Rordorf T; Ishak WZW; Hong RL; Mendoza RG; Jia L; Chirovsky D; Norquist J; Jin F; Burtness B
Oral Oncol; 2022 May; 128():105815. PubMed ID: 35381576
[TBL] [Abstract][Full Text] [Related]
13. Mapping EORTC-QLQ-C30 and QLQ-CR29 onto EQ-5D-5L in Colorectal Cancer Patients.
Ameri H; Yousefi M; Yaseri M; Nahvijou A; Arab M; Akbari Sari A
J Gastrointest Cancer; 2020 Mar; 51(1):196-203. PubMed ID: 30977049
[TBL] [Abstract][Full Text] [Related]
14. Mapping EORTC-QLQ-C30 to EQ-5D-3L in patients with colorectal cancer.
Marriott ER; van Hazel G; Gibbs P; Hatswell AJ
J Med Econ; 2017 Feb; 20(2):193-199. PubMed ID: 27676291
[TBL] [Abstract][Full Text] [Related]
15. Health-related quality of life in people with advanced dementia: a comparison of EQ-5D-5L and QUALID instruments.
Sopina E; Chenoweth L; Luckett T; Agar M; Luscombe GM; Davidson PM; Pond CD; Phillips J; Goodall S
Qual Life Res; 2019 Jan; 28(1):121-129. PubMed ID: 30187395
[TBL] [Abstract][Full Text] [Related]
16. Mapping the EORTC QLQ-C30 and QLQ-H&N35 to the EQ-5D for head and neck cancer: Can disease-specific utilities be obtained?
Beck ACC; Kieffer JM; Retèl VP; van Overveld LFJ; Takes RP; van den Brekel MWM; van Harten WH; Stuiver MM
PLoS One; 2019; 14(12):e0226077. PubMed ID: 31834892
[TBL] [Abstract][Full Text] [Related]
17. Mapping the cancer-specific QLQ-C30 onto the generic EQ-5D-5L and SF-6D in colorectal cancer patients.
Ameri H; Yousefi M; Yaseri M; Nahvijou A; Arab M; Akbari Sari A
Expert Rev Pharmacoecon Outcomes Res; 2019 Feb; 19(1):89-96. PubMed ID: 30173585
[TBL] [Abstract][Full Text] [Related]
18. Quality of Life After Bladder Cancer: A Cross-sectional Survey of Patient-reported Outcomes.
Catto JWF; Downing A; Mason S; Wright P; Absolom K; Bottomley S; Hounsome L; Hussain S; Varughese M; Raw C; Kelly P; Glaser AW
Eur Urol; 2021 May; 79(5):621-632. PubMed ID: 33581875
[TBL] [Abstract][Full Text] [Related]
19. Implications of the Quality of Life Metric in head and neck cancer.
Thom L; Lowe D; Rogers SN
Br J Oral Maxillofac Surg; 2022 Jul; 60(6):810-816. PubMed ID: 35331565
[TBL] [Abstract][Full Text] [Related]
20. Mapping EORTC QLQ-C30 and QLQ-MY20 to EQ-5D in patients with multiple myeloma.
Proskorovsky I; Lewis P; Williams CD; Jordan K; Kyriakou C; Ishak J; Davies FE
Health Qual Life Outcomes; 2014 Mar; 12():35. PubMed ID: 24618388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
